By providing access to tests for cognition, motor function, sensation, and emotion, an app may enhance patient care.

Published Date: 26 Apr 2023

Doctors can now screen patients ages 3 to 85 using an iPad app developed at Northwestern Medicine that helps measure specific aspects of cognitive, motor, sensory, and emotional function in five minutes or less.

Read Full News

Latest News

Novel imaging approach may improve treatment for spinal cord injuries

Northwestern Medicine investigators have developed a new imaging approach to more accurately assess blood flow in the spinal cord, a method that could be used to better inform treatment for neurological diseases and injuries, ...

Tirzepatide may only temporarily suppress brain 'food noise' activity

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" ...

New tool predicts graft failure after kidney transplant

Researchers at The Johns Hopkins Medicine say they have developed a new electronic medical records-based tool that should help doctors predict which patients are most at risk of losing a transplanted kidney graft.

Supercomputer simulation is changing how we study the brain

Harnessing the muscle of one of the world's fastest supercomputers, researchers have built one of the largest and most detailed biophysically realistic brain simulations of an animal ever.

AI tool creates digital twins of patients to predict their future health

A new artificial intelligence tool that can create virtual representations of patients and predict individual health trajectories has been hailed a potential gamechanger for the clinical trial sector.

How are patients using health care chatbots? Study finds some 'eye-openers'

A health care chatbot can be a patient's first point of contact for some sensitive conversations from mental health to billing, a new CU Anschutz study has found.

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Latest News

Northwestern Medicine investigators have developed a new imaging approach to more accurately assess blood flow in the spinal cord, a method that could be used to better inform treatment for neurological diseases and injuries, ...

A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain's "reward center" ...

Researchers at The Johns Hopkins Medicine say they have developed a new electronic medical records-based tool that should help doctors predict which patients are most at risk of losing a transplanted kidney graft.

Harnessing the muscle of one of the world's fastest supercomputers, researchers have built one of the largest and most detailed biophysically realistic brain simulations of an animal ever.

A new artificial intelligence tool that can create virtual representations of patients and predict individual health trajectories has been hailed a potential gamechanger for the clinical trial sector.

A health care chatbot can be a patient's first point of contact for some sensitive conversations from mental health to billing, a new CU Anschutz study has found.

News All Time

At some doctors' offices, AI is listening in the exam room

Bracken Babula starts patient visits these days by closing the exam room door and asking if they mind him recording their conversation. He hits a button on his mobile phone, checks that it is recording, and sits back in his ...

Software optimizes brain simulations, enabling them to complete complex cognitive tasks

A new software enables brain simulations which both imitate the processes in the brain in detail and can solve challenging cognitive tasks. The program was developed by a research team at the Cluster of Excellence "Machine ...

GLP-1 and health: Beyond weight loss in the Ozempic era

This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound. The move could significantly expand access to these treatments for people ...

When life imitates art: Google searches for anxiety drug spike during run of The White Lotus TV show

In season three of the hit television series "The White Lotus," the character Victoria Ratliff takes the prescription anti-anxiety medication lorazepam to help with her social anxiety and inability to sleep. Her casual usage ...

Digital access improves convenience, but cannot fully replace physical services

A research team from the Urban and Transportation Systems Laboratory, Department of Architecture and Civil Engineering, Toyohashi University of Technology, has developed an innovative evaluation framework that quantitatively ...

Deep learning system could transform skin cancer detection with near-perfect accuracy

Melanoma remains one of the hardest skin cancers to diagnose because it often mimics harmless moles or lesions. While most artificial intelligence (AI) tools rely on dermoscopic images alone, they often overlook crucial patient ...

How the brain learns and applies rules: Sequential neuronal dynamics in the prefrontal cortex

Understanding how the brain learns and applies rules is the key to unraveling the neural basis of flexible behavior. A new study from the University of Toyama, Japan, reveals that our ability to follow procedural rules is ...

Computational deep dive reveals hidden cancer drug targets and repurposing opportunities

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology.

Wireless incubator enables remote monitoring of premature infants from 30 meters away

A wireless, portable incubator that could transform care for premature infants is reported in the International Journal of Medical Engineering and Informatics. It offers remote monitoring and automated environmental control ...

Speeding the detection of three serious regional fungal infections

Certain serious fungal infections occur in regions of the United States with specific environments and are often tied to soil exposure. These infections can affect both healthy and immunocompromised people, but proper diagnosis ...

Molecular test could allow for more accurate Lyme disease diagnosis

Researchers at Dartmouth Hitchcock Medical Center have developed a way to diagnose Lyme disease earlier and more accurately than traditional testing methods.

Kidney organoids uncover Hippo signaling pathway as a therapeutic target for nephronophthisis

Using human-induced pluripotent stem cell-derived kidney organoids, researchers from Science Tokyo uncovered how abnormal Hippo signaling drives fibrosis in nephronophthisis, a genetic kidney disorder caused by NPHP1 deficiency.

FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).

FDA approves Caplyta for major depressive disorder in adults

The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder in adults.

Family history key to predicting antidepressant response

A new study from Queen Mary University of London shows that a family's experience with certain medicines could help doctors predict how future generations will respond to the same drugs.

Artificial intelligence, wellness apps alone cannot solve mental health crisis, warn experts

Emotional support is an increasingly common reason people turn to generative artificial intelligence chatbots and wellness applications, but these tools currently lack the scientific evidence and the necessary regulations ...

Recommended News For You

Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers

Childhood cancer survivors face new health problems later in life, study shows

When it comes to obesity-related cancers, where you shop for food matters

ALK-positive lung cancer trial results show unprecedented progression-free survival.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy

New imaging guidelines for head and neck cancers, a step toward practice change

Recommended Articles For You

Everything You Need to Know About the Latest Hyponatremia Algorithm  

A Comprehensive Guide To Understanding Plasma Osmolality 

CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review 

Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

NEJM: Fluorescent guide can aid in the detection of tumors that are still present after breast cancer surgery.

2.

In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.

3.

FDA Expands Durvalumab Label to Operable Lung Cancer

4.

New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations

5.

There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.

1.

The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy

2.

Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care

3.

Unveiling the Hidden Benefits of Lymphedema Treatment

4.

IGF2BP1 in Blood Disorders: Therapeutic Potential and Comprehensive Functional Insights

5.

Florinef: Understanding Its Uses and Side Effects 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

2.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV

3.

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

4.

Efficient Management of First line ALK-rearranged NSCLC - Part IV

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot